Skip to main content

Table 2 RAS peptides levels based on sensitivity analysis (*)

From: Renin–angiotensin system dysregulation in critically ill patients with acute respiratory distress syndrome due to COVID-19: a preliminary report

RAS peptides levels at study inclusion (**)

All

(n = 28)

Survivors

(n = 16)

Non-survivors

(n = 12)

P value

Renin, pg/mL median (IQR)

15.3 (6.1–79)

13 (4.5–21.3)

77.8 (10.5–256.4)

0.04

Angiotensin I, pg/mL, median (IQR)

579 (408–1156)

996 (579–1510)

439 (400–541)

0.03

Angiotensin II, pg/mL, median (IQR)

276 (217–752)

584 (240–915)

248 (209–301)

0.04

Angiotensin 1–7, pg/mL, median (IQR)

221 (174–355)

328 (214–510)

212 (168–231)

0.04

Angiotensin I/Angiotensin II ratio, median (IQR)

1.8 (1.2–2.6)

1.5 (1.2–2.8)

1.9 (1.3–2.4)

0.86

Angiotensin II/ Angiotensin 1–7 ratio, median (IQR)

1.53 (0.8–2)

1.7 (0.9–2)

1.4 (0.6–1.6)

0.2

  1. *We performed a sensitivity analysis excluding 4 patients who were taking ACEi/ARBs at study inclusion
  2. **Healthy reference ranges: renin: 1.5–20 pg/ml; Angiotensin I: median 42 [IQR: 30.5–87.3] pg/ml; Angiotensin II: 25.1 ± 5.2 pg/ml; Angiotensin (1–7): 21.0 ± 4.1 pg/ml. Direct plasma renin levels were determined by chemiluminescent immunoassay. Angiotensin compounds were measured by ELISA assay (Fine Biotech Co., Ltd)
  3. P values were calculated by Mann–Whitney test, Chi-square test and Fisher exact test, as appropriate, with a significance level of 0.05. All statistical analyses were performed using SAS 9.4 software (SAS Institute Inc, Cary, NC, USA)
Back to article page

Critical Care

ISSN: 1364-8535